ASCEND BY NTHRYS
Research Abroad Products

Molecular Oncology Project Topics

Browse all focused areas across all project categories under this field.

Showing 25–36 of 220 project topics
Gene Expression Profiling SaaS for Therapy Selection
A cloud-native platform that analyzes gene expression signatures to recommend targeted therapies, hormone therapies, and immunotherapies tailored to individual tumor profiles. Hospitals and oncology clinics increase treatment response rates by 30%, reduce off-label drug usage, and generate recurring revenue through per-test subscriptions.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
Resistance Mutation Detection and Drug Sensitivity Prediction Service
A specialized diagnostic service that identifies acquired resistance mutations in cancer patients and predicts sensitivity to next-line therapies using proprietary algorithms. Oncologists optimize treatment sequencing and avoid ineffective drugs, extending patient survival by 6-12 months while reducing healthcare costs by 20-30%.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
Multi-Cancer Early Detection Blood Test Platform
A proprietary blood testing platform that detects multiple cancer types through analysis of circulating tumor DNA, proteins, and metabolites with 85%+ sensitivity. This creates a large recurring revenue stream from screening programs while enabling earlier intervention and significantly improving patient outcomes.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
Microsatellite Instability and MSI-High Status Testing Tool
An automated diagnostic tool that rapidly identifies microsatellite instability (MSI) and mismatch repair (MMR) deficiency to stratify immunotherapy response across solid tumors. Laboratory networks and hospital systems increase testing efficiency by 50%, expand checkpoint inhibitor prescription opportunities, and improve patient outcomes for 15-20% of solid tumor cases.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
PD-L1 Expression and Tumor Microenvironment Profiling Suite
An integrated diagnostic suite that quantifies PD-L1 expression, immune infiltration, and tumor microenvironment composition to predict checkpoint inhibitor response. Oncology practices gain objective patient selection criteria, increase immunotherapy response rates by 35-45%, and generate high-margin diagnostic revenue.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
Pharmacogenomic-Guided Cancer Drug Dosing Optimization Platform
A clinical decision support platform that integrates pharmacogenomic data with tumor genetics to recommend personalized chemotherapy and targeted drug dosing regimens. Healthcare systems reduce adverse drug events by 40%, improve treatment efficacy by 25-30%, and lower hospitalization costs while monetizing through per-patient licensing and data analytics services.
Molecular Oncology Companion Diagnostic Dev Click to view more details →
Real-time Circulating Tumor DNA Detection SaaS Platform
A cloud-based software platform that processes and analyzes circulating tumor DNA (ctDNA) sequencing data in real-time, enabling oncologists to monitor treatment response and detect minimal residual disease. This platform generates recurring subscription revenue while reducing time-to-result from days to hours, creating competitive advantage for clinical laboratories and hospital networks.
Molecular Oncology Liquid Biopsy Platforms Click to view more details →
Liquid Biopsy Biomarker Discovery and Commercialization Service
A specialized service that identifies novel cancer biomarkers in blood plasma and serum, then packages them into proprietary diagnostic assays for pharmaceutical and diagnostic companies. Revenue streams include discovery contracts, licensing fees, and milestone payments as clients bring biomarker-based products to market.
Molecular Oncology Liquid Biopsy Platforms Click to view more details →
Multi-parameter Cell-free DNA Fragmentation Profiling Tool
An automated laboratory tool that measures cell-free DNA fragment size, GC-content patterns, and nucleosome positioning to create cancer-specific molecular signatures. This tool commands premium pricing by enabling non-invasive early cancer detection and treatment monitoring with superior accuracy versus conventional ctDNA methods.
Molecular Oncology Liquid Biopsy Platforms Click to view more details →
Extracellular Vesicle and Exosome Isolation Commercial System
An automated benchtop instrument that isolates and enriches cancer-derived exosomes and extracellular vesicles from blood samples with high purity and reproducibility. The system generates revenue through equipment sales, consumable cartridge subscriptions, and licensing of proprietary isolation chemistry to other diagnostics companies.
Molecular Oncology Liquid Biopsy Platforms Click to view more details →
Artificial Intelligence-powered Tumor Mutational Burden Prediction Engine
A machine learning platform that predicts tumor mutational burden (TMB) and immunotherapy response from minimal liquid biopsy data, enabling precise treatment selection before chemotherapy initiation. This creates B2B revenue through lab integration contracts and B2C revenue through direct clinical test offerings with higher reimbursement rates.
Molecular Oncology Liquid Biopsy Platforms Click to view more details →
Comprehensive Cancer Panel Sequencing Service with Liquid Biopsy
A clinical laboratory service offering targeted or whole-exome sequencing of circulating tumor DNA with interpretation reports delivered within 7-10 business days. The service generates revenue per test ($2,000-$5,000 range) with high gross margins while capturing market share from tissue-based testing through faster turnaround and non-invasive sampling.
Molecular Oncology Liquid Biopsy Platforms Click to view more details →